5 completed, 3 terminated, 3 withdrawn. 8 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 2, Withdrawn 2 |
| Phase 1 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
Follow futuximab: new trials by email Literature Review of futuximab trials Research Report on futuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer Futuximab/modotuximab, Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 7 | 2022-04-21 | 2024-08-20 |
| Sym004 Versus TAS-102 in Patients With mCRC Sym004, TAS-102 - Metastatic Colorectal Cancer, Colorectal Cancer Metastatic | Phase 3 | Withdrawn | Symphogen A/S | 2019-02-01 | 2019-02-04 | |
| Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Sym004, Futuximab, Modotuximab - Metastatic Colorectal Cancer, Colorectal Cancer Metastatic | Phase 2 | Terminated | Symphogen A/S | 2 | 2018-11-29 | 2020-09-28 |
| Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Sym004 - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Symphogen A/S | 2016-12-01 | 2017-02-01 | |
| Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Sym004, Nivolumab - Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Symphogen A/S | 2016-11-01 | 2017-08-28 | |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Sym004, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Symphogen A/S | 10 | 2016-03-15 | 2019-03-26 |
| Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Sym004 - 18 mg/kg, Sym004 - 24 mg/kg - Malignant Glioma | Phase 2 | Completed | Annick Desjardins | 43 | 2016-02-01 | 2020-08-05 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC) - Metastatic Colorectal Cancer | Phase 2 | Completed | Symphogen A/S | 254 | 2014-03-06 | 2019-04-16 |
| Japanese Phase 1 Trial of Sym004 in Solid Tumors Sym004 - Solid Tumors | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 51 | 2013-10-31 | 2017-08-23 |
| Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy Sym004 - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | Symphogen A/S | 26 | 2011-07-01 | 2018-10-15 |
| Sym004 in Patients With Advanced Solid Tumors Sym004 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Symphogen A/S | 111 | 2010-03-01 | 2018-10-15 |
Colorectal Neoplasms (7) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Glioma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Symphogen A/S (8) · Annick Desjardins (1) · Institut de Recherches Internationales Servier (1) · Merck KGaA, Darmstadt, Germany (1)
United States (6) · Belgium (4) · Germany (4) · Spain (4) · France (2) · Hungary (2) · Italy (2) · Austria (1) · Denmark (1) · Finland (1) · Japan (1) · Poland (1) · Russia (1)
Josep Tabernero, MD, PhD (4) · Annick Desjardins, MD, FRCPC (1) · Fortunato Ciardiello (1) · Ivan Horak, MD, FACP (1) · Scott Kopetz, MD,PhD,FACP (1)
PMID 25952795, PMID 25962717, PMID 30099818
2018 (2), 2009 (1), 2015 (1), 2016 (1)